期刊
ADVANCED SCIENCE
卷 8, 期 19, 页码 -出版社
WILEY
DOI: 10.1002/advs.202004673
关键词
chromatin remodeling; colorectal cancer; DPP4; epigenetics; hepatic growth factor (HGF); metastasis; PU; 1
资金
- NIH [U01-CA214300, U01-CA217514, P30-CA014236-44]
- Strategic Priority Research Program of the Chinese Academy of Science [XDB29040100]
- Chinese Ministry of Science and Technology [2017YFA0504103]
- National Natural Science Foundation of China [31771513, 81972797, 81921003]
- [R01 CA237304]
Metastatic colorectal cancer cells undergo specific chromatin remodeling in the liver, facilitated by hepatic growth factor-induced phosphorylation of PU.1. This epigenetic modification allows for the growth of tumor cells in their new niche and could potentially be targeted for therapeutic intervention. Individual genetic silencing or pharmacological inhibition along this chromatin remodeling axis can strongly suppress liver metastasis.
Colorectal cancer (CRC) metastasizes mainly to the liver, which accounts for the majority of CRC-related deaths. Here it is shown that metastatic cells undergo specific chromatin remodeling in the liver. Hepatic growth factor (HGF) induces phosphorylation of PU.1, a pioneer factor, which in turn binds and opens chromatin regions of downstream effector genes. PU.1 increases histone acetylation at the DPP4 locus. Precise epigenetic silencing by CRISPR/dCas9(KRAB) or CRISPR/dCas9(HDAC) revealed that individual PU.1-remodeled regulatory elements collectively modulate DPP4 expression and liver metastasis growth. Genetic silencing or pharmacological inhibition of each factor along this chromatin remodeling axis strongly suppressed liver metastasis. Therefore, microenvironment-induced epimutation is an important mechanism for metastatic tumor cells to grow in their new niche. This study presents a potential strategy to target chromatin remodeling in metastatic cancer and the promise of repurposing drugs to treat metastasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据